Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

The settlement resolves the Attorney General’s 2018 lawsuit alleging that Novo Nordisk deceptively priced its insulin.

The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

Eli Lilly is just weeks away from launching Mounjaro ... first major market to be supplied with the drug in the multi-shot pen injector format. Like the earlier single-dose version, which was ...

Two years ago, Eli Lilly started working with Dexcom to integrate ... app-based remote monitoring and alarm functions – in pen- and pump-based insulin systems that form the basis of the ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

BMO Capital Markets affirmed their positive stance on Novo Nordisk (NYSE:NVO) stock, maintaining both their Outperform rating and a $105.00 price target. The endorsement comes in the wake of promising ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...